Peptide Report
CJC 1295 + IPA Peptide Report
Catalog report for CJC 1295 + IPA, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.
Current Price$75.00 – $150.00 CAD
Common Uses
People commonly use CJC-1295 + Ipamorelin for growth-hormone support routines connected with sleep quality, recovery, lean body composition, and training adaptation.
How It Works
CJC-1295 + Ipamorelin combines a GHRH analog with a ghrelin-receptor secretagogue. Together they are used to stimulate pituitary growth-hormone release through complementary pathways: GHRH receptor signaling and GHSR-1a activation.
Storage
Powder form: In lyophilized powder form, CJC 1295 + IPA is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.
Reconstituted: After reconstitution, CJC 1295 + IPA should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.
Protocol
The full CJC-1295 + Ipamorelin protocol is included below. The standalone protocol page remains available if you want to open it separately.
Open Standalone Protocol
Scope
Reconstitution examples, component conversion and community-reported usage patterns.
Available strengths: 10 MG and 20 MG combined
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup |
Diluent |
Concentration |
Unit conversion |
| 10 MG combined vial (5/5 MG) |
Add 2.5 mL bacteriostatic water |
2 mg/mL of each component |
Each U-100 unit = 20 mcg of each |
| 20 MG combined vial (10/10 MG) |
Add 2.5 mL bacteriostatic water |
4 mg/mL of each component |
Each U-100 unit = 40 mcg of each |
Syringe Conversion
| Each component |
10 MG setup |
20 MG setup |
| 100 mcg + 100 mcg |
5 units |
2.5 units |
| 150 mcg + 150 mcg |
7.5 units |
3.75 units |
| 200 mcg + 200 mcg |
10 units |
5 units |
| 250 mcg + 250 mcg |
12.5 units |
6.25 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
| Recurring report |
Frequency seen |
Timing in reports |
| 100/100 mcg |
Once daily |
Often bedtime, separated from food |
| 100/200 mcg |
Once or twice daily |
Morning and/or bedtime |
| 200/200 mcg |
Once daily, often Mon-Fri |
Morning or bedtime |
Observations
- The reviewed reports most often clustered around 100-200 mcg of each component per administration.
- Some users split morning and evening administrations; others moved dosing to morning after sleep disruption.
- Reported food timing and cycle length varied, and no community consensus was evident.
Caveats
- Posts discussed sleep changes, tingling or numbness, water retention and limited biomarker response; these reports are uncontrolled anecdotes.
- Confirm whether a product contains CJC-1295 with DAC or no DAC. They are not interchangeable, and this document addresses the combined PeptideStacks product only.